An ongoing clinical trial proposes that CAN-2409 viral immunotherapy could potentially induce T cells to further infiltrate tumor cells, and consequently upregulate PD-L1, enhancing ICI therapy (NCT04495153). The gene discussed is CD274; the disease is neoplasm.